{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:32:24Z","timestamp":1787758344310,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The management of acute respiratory failure in COVID-19 patients and the role and limitations of high-flow nasal oxygen therapy (HFNOT) remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study aimed to investigate the effect of HFNOT, identify the characteristics of patients who will benefit from therapy, and determine monitoring strategies to decide on endotracheal intubation for patients with COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>We conducted a prospective observational study of COVID-19 patients who were admitted to the intensive care unit (ICU) and required HFNOT for at least 2 days between 20 March 2020 and 20 June 2020. The exclusion criteria were a severe respiratory failure, reduced levels of consciousness, combination with other noninvasive ventilation strategies, and exhaustion. The patients were followed up until ICU discharge. The primary outcome was the proportion of patients with COVID-19 who were successfully weaned from HFNOT, whereas failure comprised intubation or death on HFNOT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-five subjects (24 males, mean-age: 61.62, standard deviation: 14.9 yr.) were included in the study. A total of 20\/35 (57.1%) subjects survived to discharge. C-reactive-protein (CRP) and interleukin-6 (IL-6) levels were significantly increased in the treatment failure group (CRP; effect size (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      ):0.35,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      : 0.037, IL-6;\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      : 0.37,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      : 0.03). Although there was a difference between repeated measures of partial-pressure-of-oxygen\/fraction-of-inspired-oxygen (PaO\n                      <jats:sub>2<\/jats:sub>\n                      \/FiO\n                      <jats:sub>2<\/jats:sub>\n                      :P\/F) rates (partial-eta-squared (\u03b7\n                      <jats:sub>p<\/jats:sub>\n                      <jats:sup>2<\/jats:sup>\n                      ):0.79,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), no difference was found between carbon dioxide levels (\u03b7\n                      <jats:sub>p<\/jats:sub>\n                      <jats:sup>2<\/jats:sup>\n                      :0.29,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      : 0.44). There was also no difference between ROX (ratio-of-oxygen-saturation\/FiO\n                      <jats:sub>2<\/jats:sub>\n                      to respiratory-rate) rates (Kendall's W: 0.33\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.310).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In COVID-19 patients with mild-to-moderate dyspnea and hypoxemia who are nonresponsive to conventional-oxygen-therapies, the initial approach may involve the use of HFNOT. In this study, patient monitoring could be performed with ROX and P\/F ratios, and the effectiveness of the treatment could be decided by looking at these rates in the second hour. Prolongation of the period and awake prone positioning did not improve the outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_1646_21","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T07:43:08Z","timestamp":1663746188000},"page":"1088-1093","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Role and Limitations of High-Flow Nasal Oxygen Therapy in COVID-19 Patients"],"prefix":"10.4103","volume":"25","author":[{"given":"P","family":"Kucukdemirci-Kaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kelebek-Girgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-17-20240907","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"R3-17-20240907","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of Covid-19 in New York City","volume":"382","author":"Goyal","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-17-20240907","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5578\/tt.69807","article-title":"High flow nasal cannula in COVID-19: A literature review","volume":"68","author":"G\u00fcr\u00fcn Kaya","year":"2020","journal-title":"Tuberk Toraks"},{"key":"R5-17-20240907","first-page":"63","article-title":"High-flow nasal oxygen therapy","volume":"17","author":"Ashraf-Kashani","year":"2017","journal-title":"Br J Anaesth Education"},{"key":"R6-17-20240907","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4187\/respcare.06718","article-title":"High-flow nasal cannula oxygen therapy devices","volume":"64","author":"Nishimura","year":"2019","journal-title":"Respiratory Care"},{"key":"R7-17-20240907","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s12630-020-01740-2","article-title":"High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: Systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission","volume":"67","author":"Agarwal","year":"2020","journal-title":"J Can Anesth"},{"key":"R8-17-20240907","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1097\/CCM.0000000000004363","article-title":"Surviving Sepsis Campaign: Guidelines on the Management of Critically III Adults with Coronavirus Disease 2019 (COVID-19)","volume":"48","author":"Alhazzani","year":"2020","journal-title":"Critical Care Medicine"},{"key":"R9-17-20240907","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12871-020-01095-7","article-title":"Management of respiratory distress syndrome due to COVID-19 infection","volume":"20","author":"Navas-Blanco","year":"2020","journal-title":"BMC Anesthesiol"},{"key":"R10-17-20240907","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00134-020-06033-2","article-title":"COVID-19 pneumonia: Different respiratory treatments for different phenotypes?","volume":"46","author":"Gattinoni","year":"2020","journal-title":"Intensive Care Med"},{"key":"R11-17-20240907","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/j.bja.2020.04.012","article-title":"COVID-19 patients with respiratory failure: What can we learn from aviation medicine?","volume":"125","author":"Ottestad","year":"2020","journal-title":"Br J Anaesth"},{"key":"R12-17-20240907","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bja.2020.08.050","article-title":"COVID-19-related organ dysfunction and management strategies on the intensive care unit: A narrative rewiew","volume":"125","author":"Sherren","year":"2020","journal-title":"Br J Anaesth"},{"key":"R13-17-20240907","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa1503326","article-title":"High flow oxygen through nasal cannula in hypoxemic respiratory failure","volume":"372","author":"Frat","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-17-20240907","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00134-019-05658-2","article-title":"High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: A systematic rewiew and meta-analysis","volume":"45","author":"Rochwerg","year":"2019","journal-title":"Intensive Care Med"},{"key":"R15-17-20240907","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13054-020-2738-5","article-title":"Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: A multi-centre prospective cohort study","volume":"24","author":"Ding","year":"2020","journal-title":"Crit Care"},{"key":"R16-17-20240907","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.bja.2020.12.017","article-title":"Association between inflammation, angiopoietins, and disease severity in critically ill COVID-19 patients: A prospective study","volume":"126","author":"Abou-Arab","year":"2021","journal-title":"Br J Anaesth"},{"key":"R17-17-20240907","doi-asserted-by":"crossref","first-page":"104370","DOI":"10.1016\/j.jcv.2020.104370","article-title":"Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19","volume":"127","author":"Liu","year":"2020","journal-title":"J Clin Virol"},{"key":"R18-17-20240907","first-page":"100570","article-title":"The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in are source-constrained settings: A multi-centre prospective observational study","volume":"28","author":"Calligaro","year":"2020","journal-title":"E Clin Med"},{"key":"R19-17-20240907","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ppul.24216","article-title":"Effect of high frequency oscillatory high flow nasal cannula on carbon dioxide clearance in a premature infant lung model: A bench study","volume":"54","author":"Sivieri","year":"2019","journal-title":"Pediatr Pulmonol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_1646_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:14:36Z","timestamp":1787757276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_1646_21"}},"subtitle":["An Observational Study"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_1646_21","relation":{},"ISSN":["1119-3077"],"issn-type":[{"value":"1119-3077","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}